"We're now translating our basic research into human studies to explore whether RORDEP-producing bacteria or the RORDEP proteins—either in their natural or chemically modified form—can serve as the foundation for a new class of biological drugs known as pharmabiotics," says Professor Oluf Pedersen from the University of Copenhagen, project leader and senior author of the new study.
He adds, "Looking 10 to 15 years ahead, our goal is to test the potential of RORDEP-producing bacteria for both prevention and treatment. We want to investigate whether they can function as a second-generation probiotic—used as a dietary supplement to prevent common chronic diseases—and whether RORDEP-proteins in modified forms can be developed into future medicines for cardiovascular disease, obesity, diabetes, and osteoporosis."
